GSK plc is paying Wave Life Sciences Ltd. $170m upfront for global rights to its preclinical asset, WVE-006, as well as a collaboration to develop oligonucleotides which has prompted analysts to tout the benefits of a partnership model for the US biotech.
Wave Banks $170m Upfront In GSK Oligonucleotide Deal, Analysts Back Shift To Partnership Model
Lucrative Potential Milestones
The US biotech has out-licensed a preclinical candidate to GSK as the firms pair up to discover and develop multiple oligonucleotide assets.
More from Business
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
More from Scrip
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.